We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prestige Consumer (PBH) Up on Q1 Earnings & Revenue Beat
Read MoreHide Full Article
Shares of Prestige Consumer Healthcare Inc. (PBH - Free Report) rose nearly 2% in the aftermarket trading session on Aug 6, following its first-quarter fiscal 2021 results, wherein both top and bottom lines beat the Zacks Consensus Estimate. This marked the company’s sixth straight beat (on a combined basis). Despite the pandemic, results gained from solid e-commerce performance along with strong free cash flow, which was driven by EBITDA growth and a disciplined capital allocation strategy. However, management refrained from providing any full-year guidance, citing the uncertainties surrounding the ongoing COVID-19 situation.
Quarter in Detail
The company posted adjusted earnings of 86 cents per share, which surpassed the Zacks Consensus Estimate of 70 cents. This marked its 10th consecutive quarter of earnings beat. Quarterly earnings also improved 32.3% year over year.
Total revenues fell 1.2% to $229.4 million but surpassed the Zacks Consensus Estimate of $222 million. Organic revenues edged down 0.6% (excluding currency effects). The downside can be attributable to lower consumption for certain product categories, stemming from ongoing COVID-19 pandemic. On the flip side, robust consumption trends in most of the company’s products and gains from higher retailer orders provided some cushion to the stock.
Gross profit came in at $133.9 million, down 0.1% from the prior-year quarter’s figure. Meanwhile, gross margin expanded 70 basis points (bps) to 58.4%.
Adjusted EBITDA was $87.6 million, up 12.1% year over year. However, adjusted EBITDA margin expanded 450 bps to 38.2%.
Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise
Revenues in the North American OTC Healthcare segment were $210.7 million, down 0.05% year over year. This is mainly due to sluggish consumption in certain product categories, which have been hurt by the ongoing COVID-19 crisis. However, gains related to higher retailer order patterns aided results.
Revenues in the International OTC Healthcare segment totaled $18.7 million, down 12.3% from the year-ago quarter’s figure. The downside can be attributed to higher retailer order patterns. This was partly negated by sluggish consumption in certain product categories and currency headwinds of roughly $1 million.
Financial Updates
The company exited the quarter with cash and cash equivalents of $57.9 million, long-term debt (net) of $1,620.6 million and total shareholders’ equity of approximately $1,227 million.
Net cash provided by operating activities in the reported quarter was $75.2 million. Adjusted free cash flow for the fiscal amounted to $72.6 million. As of Jun 30, the company’s net debt position was about $1.6 billion. In the quarter under review, Prestige Consumer lowered debt by $111 million.
Q2 Guidance
Management now anticipates revenues in the fiscal second quarter to be at least $225 million. Also, the bottom line is expected to be at least 70 cents during the second quarter, driven by cost management policies. The guidance includes sudden changes in consumer preferences and supply-chain disruptions as a result of the ongoing COVID-19 pandemic.
Price Performance
This Zacks Rank #3 (Hold) stock has gained 1.3% in the past three months against the industry’s decline of 13.4%.
Looking for High-Performance Stocks? Here’re a Few
Campbell Soup Company (CPB - Free Report) has a long-term earnings growth rate of 8.3% and a Zacks Rank #2 (Buy).
Kraft Heinz Company (KHC - Free Report) has a long-term earnings growth rate of 6% and a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Prestige Consumer (PBH) Up on Q1 Earnings & Revenue Beat
Shares of Prestige Consumer Healthcare Inc. (PBH - Free Report) rose nearly 2% in the aftermarket trading session on Aug 6, following its first-quarter fiscal 2021 results, wherein both top and bottom lines beat the Zacks Consensus Estimate. This marked the company’s sixth straight beat (on a combined basis). Despite the pandemic, results gained from solid e-commerce performance along with strong free cash flow, which was driven by EBITDA growth and a disciplined capital allocation strategy. However, management refrained from providing any full-year guidance, citing the uncertainties surrounding the ongoing COVID-19 situation.
Quarter in Detail
The company posted adjusted earnings of 86 cents per share, which surpassed the Zacks Consensus Estimate of 70 cents. This marked its 10th consecutive quarter of earnings beat. Quarterly earnings also improved 32.3% year over year.
Total revenues fell 1.2% to $229.4 million but surpassed the Zacks Consensus Estimate of $222 million. Organic revenues edged down 0.6% (excluding currency effects). The downside can be attributable to lower consumption for certain product categories, stemming from ongoing COVID-19 pandemic. On the flip side, robust consumption trends in most of the company’s products and gains from higher retailer orders provided some cushion to the stock.
Gross profit came in at $133.9 million, down 0.1% from the prior-year quarter’s figure. Meanwhile, gross margin expanded 70 basis points (bps) to 58.4%.
Adjusted EBITDA was $87.6 million, up 12.1% year over year. However, adjusted EBITDA margin expanded 450 bps to 38.2%.
Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise
Prestige Consumer Healthcare Inc. price-consensus-eps-surprise-chart | Prestige Consumer Healthcare Inc. Quote
Segment Performance
Revenues in the North American OTC Healthcare segment were $210.7 million, down 0.05% year over year. This is mainly due to sluggish consumption in certain product categories, which have been hurt by the ongoing COVID-19 crisis. However, gains related to higher retailer order patterns aided results.
Revenues in the International OTC Healthcare segment totaled $18.7 million, down 12.3% from the year-ago quarter’s figure. The downside can be attributed to higher retailer order patterns. This was partly negated by sluggish consumption in certain product categories and currency headwinds of roughly $1 million.
Financial Updates
The company exited the quarter with cash and cash equivalents of $57.9 million, long-term debt (net) of $1,620.6 million and total shareholders’ equity of approximately $1,227 million.
Net cash provided by operating activities in the reported quarter was $75.2 million. Adjusted free cash flow for the fiscal amounted to $72.6 million. As of Jun 30, the company’s net debt position was about $1.6 billion. In the quarter under review, Prestige Consumer lowered debt by $111 million.
Q2 Guidance
Management now anticipates revenues in the fiscal second quarter to be at least $225 million. Also, the bottom line is expected to be at least 70 cents during the second quarter, driven by cost management policies. The guidance includes sudden changes in consumer preferences and supply-chain disruptions as a result of the ongoing COVID-19 pandemic.
Price Performance
This Zacks Rank #3 (Hold) stock has gained 1.3% in the past three months against the industry’s decline of 13.4%.
Looking for High-Performance Stocks? Here’re a Few
Spectrum Brands (SPB - Free Report) has an expected long-term earnings growth rate of 16.3% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Campbell Soup Company (CPB - Free Report) has a long-term earnings growth rate of 8.3% and a Zacks Rank #2 (Buy).
Kraft Heinz Company (KHC - Free Report) has a long-term earnings growth rate of 6% and a Zacks Rank #2.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>